Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a short-term renal hemodynamic study of tolvaptan in ADPKD
NL-OMON34527Phase 2Active, not recruiting
- Sponsor
- Covance
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Covance. Primary endpoints: Measured glomerular filtration rate, Effective renal plasma flow and 1 more. Started Sep 2011; status: active, not recruiting.
02
Drugs
tolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NL-OMON34527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34527.